Article · 30 Apr 2025
OtherPublished 22 Jul 2016
The treatment of advanced non-small-cell lung cancer with anaplastic lymphoma kinase genetic alterations: reality and hopes
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Targeted therapies based on molecular diagnostics have opened a new era of personalized medicine in lung cancer treatment. Recently, anaplastic lymphoma kinase (ALK) fusion gene emerged as an important biomarker for identifying a small proportion of non-small-cell lung cancer (NSCLC) patients that will benefit from ALK kinase inhibitor crizotinib, like EGFR activating mutations and EGFR tyrosine kinase inhibitors. Despite the remarkable initial responses, acquired resistance to crizotinib develops within a year and promising second generation of ALK inhibitors are in current development to overcome it. This review will focus on the basic molecular pathology of ALK gene rearrangement in NSCLC, current testing methods, treatment strategies against ALK-positive and crizotinib-resistant NSCLCs.
Keywords
Subjects
General & Internal MedicineAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Clinical Investigation.
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalClinical Investigation
- SubjectGeneral & Internal Medicine
- BylineArticles whose byline prints “Assunta Sgambato”
- BylineArticles whose byline prints “Francesca Casaluce”
- BylineArticles whose byline prints “Antonio Rossi”
- BylineArticles whose byline prints “Paolo Maione”
- BylineArticles whose byline prints “Paola Claudia Sacco”
- BylineArticles whose byline prints “Fortunato Ciardiello & Cesare Gridelli”